Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 58.7%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large drop in short interest in December. As of December 31st, there was short interest totalling 31,500 shares, a drop of 58.7% from the December 15th total of 76,200 shares. Based on an average daily volume of 787,700 shares, the days-to-cover ratio is currently 0.0 days.

Astellas Pharma Trading Up 0.1 %

Shares of ALPMY stock opened at $9.48 on Tuesday. The company has a market capitalization of $17.16 billion, a P/E ratio of 45.15 and a beta of 0.34. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $10.17 and a 200 day moving average price of $11.02.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, October 30th. The company reported $0.13 EPS for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. The business had revenue of $3.11 billion for the quarter. Research analysts forecast that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.